If the body lacks the protective protein alpha-1 antitrypsin (AAT), life-threatening damage to the liver and lungs can occur. A research team, with the involvement of the DZL, has developed a revolutionary therapy that repairs...
Researchers from the DZL site BREATH have identified a previously unknown link between pathogenic variants in the DGUOK gene and the rare lung disease pleuroparenchymal fibroelastosis (PPFE).
To mark the 15th anniversary of the German Centers for Health Research (DZG), the DZG and Helmholtz Health will jointly present the program “Future of Medicine: From Discovery to Impact” at the Falling Walls Science...
A German multicenter study investigates the real-world effects of dupilumab in people with COPD and type 2 inflammation. The findings provide new insights into the potential of this antibody therapy.
The EU-funded research project BREATH-EC is developing an innovative cell therapy approach designed to halt the progression of pulmonary fibrosis and potentially regenerate damaged lung tissue.
Why do some children develop persistent asthma after experiencing wheezing early in life, while others become symptom-free? Researchers at the German Center for Lung Research (DZL) have shown that distinct immune programs can already be...
For 15 years, the Lung Information Service has provided evidence-based information on lung diseases. As a long-standing partner of the DZL, it helps make findings from lung research accessible and understandable to patients and the...
DZL researchers at the ARCN site have modified a naturally occurring anti-inflammatory messenger molecule to prolong its activity in the body. In a mouse model, the modified version of interleukin-37 significantly reduced airway inflammation and...
The XeNid research project at Hannover Medical School is investigating how genetically modified pig organs could serve as temporary replacements until a human donor organ becomes available.
A German-Serbian research project led by DZL scientist Dr. Stefan Hadzic is investigating how altered proteins contribute to COPD severity and progression – and how the resulting misguided immune response could be selectively blocked.
DZL researchers show that triple therapy can almost completely restore CFTR function in children with cystic fibrosis. The effect was particularly pronounced in younger children, highlighting the potential benefits of early treatment.
DZL scientist Prof. Dr. Matthias Griese has received the ERS Lifetime Achievement Award in Paediatrics 2026 for his outstanding contributions to paediatric pneumology and his longstanding commitment to children with rare and severe lung diseases.
